West Pharmaceutical Services, Inc. (WST) Tops Q3 EPS by 1c; Lowers FY11 EPS Outlook
West Pharmaceutical Services, Inc. (NYSE: WST) reported Q3 EPS of $0.53, $0.01 better than the analyst estimate of $0.52. Revenue for the quarter came in at $293.6 million versus the consensus estimate of $289.25 million.
Sees FY2011 EPS of $2.28-$2.35, versus prior guidance of $2.30-$2.40 and the consensus of $2.35. Sees FY2011 revenue of $1.18-$1.20 billion, versus prior guidance of $1.17-$1.20 billion and the consensus of $1.19 billion.
Sees FY2011 EPS of $2.28-$2.35, versus prior guidance of $2.30-$2.40 and the consensus of $2.35. Sees FY2011 revenue of $1.18-$1.20 billion, versus prior guidance of $1.17-$1.20 billion and the consensus of $1.19 billion.